RBC Capital Keeps Their Buy Rating on AdaptHealth (AHCO)

In a report released yesterday, Ben Hendrix from RBC Capital maintained a Buy rating on AdaptHealth, with a price target of $13.00. The company’s shares closed yesterday at $8.86.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Hendrix covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, CVS Health, and Tenet Healthcare. According to TipRanks, Hendrix has an average return of 6.4% and a 53.06% success rate on recommended stocks.

Currently, the analyst consensus on AdaptHealth is a Moderate Buy with an average price target of $13.50, a 52.46% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to a Buy with a $11.50 price target.

Based on AdaptHealth’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $846.29 million and a GAAP net loss of $102.77 million. In comparison, last year the company earned a revenue of $856.65 million and had a net profit of $50.26 million

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AHCO in relation to earlier this year. Most recently, in December 2025, David Solomon III Williams, a Director at AHCO sold 5,000.00 shares for a total of $47,150.00.